Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Pinato DJ, et al. Among authors: pazdur r. Eur J Cancer. 2021 Nov;157:140-152. doi: 10.1016/j.ejca.2021.08.020. Epub 2021 Sep 8. Eur J Cancer. 2021. PMID: 34508996
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Kane RC, et al. Among authors: pazdur r. Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Oncologist. 2009. PMID: 19144678 Free article. Review.
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R. Kwitkowski VE, et al. Among authors: pazdur r. Oncologist. 2010;15(4):428-35. doi: 10.1634/theoncologist.2009-0178. Epub 2010 Mar 23. Oncologist. 2010. PMID: 20332142 Free PMC article. Clinical Trial.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R. Lemery SJ, et al. Among authors: pazdur r. Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2. Clin Cancer Res. 2010. PMID: 20601446
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Casak SJ, Lemery SJ, Shen YL, Rothmann MD, Khandelwal A, Zhao H, Davis G, Jarral V, Keegan P, Pazdur R. Casak SJ, et al. Among authors: pazdur r. Oncologist. 2011;16(1):97-104. doi: 10.1634/theoncologist.2010-0306. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212432 Free PMC article. Review.
Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, Zhao H, Marathe A, Kotch L, Jee J, Wang Y, Zhou L, Adams WM, Jarral V, Pilaro A, Lostritto R, Gootenberg JE, Keegan P, Pazdur R. Donoghue M, et al. Among authors: pazdur r. Clin Cancer Res. 2012 Mar 15;18(6):1496-505. doi: 10.1158/1078-0432.CCR-11-2149. Epub 2012 Jan 26. Clin Cancer Res. 2012. PMID: 22282463
605 results